ICCC logo

ImmuCell Corporation

ICCC
Healthcare|Biotechnology|US
$9.80
-0.15 (-1.51%)
Tangible Book / Share
$3.45
Graham Number
$2.60
Cash / Share
$0.98

About

ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.

Stock Price

+55.3%(1Y)
1M
+0.5%
3M
-10.9%
6M
+21.7%
YTD
+59.3%
1Y
+61.2%
3Y
+79.3%
5Y
+5.7%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$89.0M
Employees73 (-3% YoY)
CEOF. Olivier Te Boekhorst
IPO DateMay 5, 1987
Beta0.62
52-Week Range$4.52 – $12.1
Avg Volume19,867
ExchangeNASDAQ

Ownership

Float66.4%
Shares Outstanding9.1M

Recent Insider Trades

te Boekhorst Paul Francis OlivierBUY
Jun 18, 20268,000 shares @ $9.49
DiMarco AnthonyOTHER
Apr 15, 202617,899 shares @ $7.60
Guillemette GillesOTHER
Apr 15, 202617,899 shares @ $7.60
Turner Kathy VAWARD
Apr 15, 202617,899 shares @ $7.60
Tomsche David ScottAWARD
Apr 15, 202611,933 shares @ $7.60

Peers

COEPCoeptis Therapeutics Holdings, Inc.
$38.6M
CUECue Biopharma, Inc.
$136.1M
EQEquillium, Inc.
$95.7M
FBIOFortress Biotech, Inc.
$61.7M
GNTAGenenta Science S.p.A.
$18.0M
IPSCCentury Therapeutics, Inc.
$304.2M
NRXPNRx Pharmaceuticals, Inc.
$103.0M
OSTXOS Therapies Incorporated
$46.8M
Data last updated: Nov 9, 2026, 04:14 AM